Free Trial

Talphera (TLPH) Competitors

$1.03
-0.01 (-0.96%)
(As of 05/24/2024 ET)

TLPH vs. NERV, BIOR, AYTU, TCRT, VBIV, GLYC, KALA, BIVI, GLTO, and ORGS

Should you be buying Talphera stock or one of its competitors? The main competitors of Talphera include Minerva Neurosciences (NERV), Biora Therapeutics (BIOR), Aytu BioPharma (AYTU), Alaunos Therapeutics (TCRT), VBI Vaccines (VBIV), GlycoMimetics (GLYC), KALA BIO (KALA), BioVie (BIVI), Galecto (GLTO), and Orgenesis (ORGS). These companies are all part of the "pharmaceutical preparations" industry.

Talphera vs.

Minerva Neurosciences (NASDAQ:NERV) and Talphera (NASDAQ:TLPH) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their risk, analyst recommendations, community ranking, dividends, valuation, profitability, earnings, institutional ownership and media sentiment.

Minerva Neurosciences received 343 more outperform votes than Talphera when rated by MarketBeat users. However, 100.00% of users gave Talphera an outperform vote while only 60.45% of users gave Minerva Neurosciences an outperform vote.

CompanyUnderperformOutperform
Minerva NeurosciencesOutperform Votes
347
60.45%
Underperform Votes
227
39.55%
TalpheraOutperform Votes
4
100.00%
Underperform Votes
No Votes

Talphera's return on equity of 0.00% beat Minerva Neurosciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Minerva NeurosciencesN/A N/A -53.19%
Talphera N/A -96.30%-63.20%

Minerva Neurosciences has a beta of 0.27, indicating that its share price is 73% less volatile than the S&P 500. Comparatively, Talphera has a beta of 0.46, indicating that its share price is 54% less volatile than the S&P 500.

In the previous week, Talphera had 1 more articles in the media than Minerva Neurosciences. MarketBeat recorded 2 mentions for Talphera and 1 mentions for Minerva Neurosciences. Talphera's average media sentiment score of 1.89 beat Minerva Neurosciences' score of 0.72 indicating that Minerva Neurosciences is being referred to more favorably in the media.

Company Overall Sentiment
Minerva Neurosciences Very Positive
Talphera Positive

34.6% of Minerva Neurosciences shares are owned by institutional investors. Comparatively, 37.7% of Talphera shares are owned by institutional investors. 6.4% of Minerva Neurosciences shares are owned by company insiders. Comparatively, 3.0% of Talphera shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Minerva Neurosciences currently has a consensus price target of $7.00, suggesting a potential upside of 186.71%. Talphera has a consensus price target of $4.50, suggesting a potential upside of 336.89%. Given Minerva Neurosciences' stronger consensus rating and higher possible upside, analysts plainly believe Talphera is more favorable than Minerva Neurosciences.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Minerva Neurosciences
0 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
2.00
Talphera
0 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
3.00

Talphera has higher revenue and earnings than Minerva Neurosciences. Talphera is trading at a lower price-to-earnings ratio than Minerva Neurosciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Minerva NeurosciencesN/AN/A-$30M-$4.47-0.55
Talphera$650K26.92-$18.40M-$0.89-1.16

Summary

Talphera beats Minerva Neurosciences on 10 of the 16 factors compared between the two stocks.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TLPH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

TLPH vs. The Competition

MetricTalpheraPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$17.50M$6.83B$5.18B$8.07B
Dividend YieldN/A2.76%2.76%3.95%
P/E Ratio-1.169.0895.4013.94
Price / Sales26.92247.002,508.0773.23
Price / CashN/A32.8335.9931.33
Price / Book1.075.705.414.56
Net Income-$18.40M$140.12M$106.26M$214.11M
7 Day Performance-4.63%-2.36%-1.30%-1.04%
1 Month Performance-1.90%1.31%2.72%3.13%
1 Year PerformanceN/A-5.43%4.83%7.38%

Talphera Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
NERV
Minerva Neurosciences
3.8309 of 5 stars
$2.52
+0.8%
$7.00
+177.8%
-61.6%$17.62MN/A-0.569Analyst Forecast
Positive News
BIOR
Biora Therapeutics
2.6114 of 5 stars
$0.50
-27.7%
$15.00
+2,918.1%
-86.7%$17.83MN/A-0.0758Gap Up
High Trading Volume
AYTU
Aytu BioPharma
3.2653 of 5 stars
$3.20
+2.6%
$5.00
+56.3%
+90.5%$17.38M$93.76M-1.22150Positive News
TCRT
Alaunos Therapeutics
0 of 5 stars
$1.08
+0.9%
N/A-87.2%$17.29MN/A0.001Gap Down
VBIV
VBI Vaccines
1.351 of 5 stars
$0.63
-1.6%
N/A-76.7%$18.07M$9.41M0.00131Negative News
Gap Up
GLYC
GlycoMimetics
3.6819 of 5 stars
$0.27
-3.5%
$10.00
+3,560.3%
-84.5%$18.20M$10,000.00-0.4735Analyst Forecast
KALA
KALA BIO
3.8379 of 5 stars
$6.50
-0.2%
$16.50
+153.8%
-55.9%$18.34M$3.89M-0.4343High Trading Volume
BIVI
BioVie
0.8437 of 5 stars
$0.46
-4.2%
$8.00
+1,639.1%
-92.9%$18.36MN/A-0.4918Gap Down
GLTO
Galecto
2.0541 of 5 stars
$0.62
flat
$5.33
+760.2%
-72.3%$16.81MN/A-0.5413News Coverage
ORGS
Orgenesis
1.7638 of 5 stars
$0.49
flat
N/A-59.3%$16.70M$530,000.000.00146Gap Up

Related Companies and Tools

This page (NASDAQ:TLPH) was last updated on 5/26/2024 by MarketBeat.com Staff

From Our Partners